ModerateVitamin K antagonist anticoagulants×Selective serotonin reuptake inhibitors
Updated · Methodology
Mechanism
Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list fluoxetine among the selective serotonin reuptake inhibitors (SSRIs) that can potentiate its anticoagulant effect (AEMPS). The Spanish fluoxetine SmPC groups oral anticoagulants with drugs that affect haemostasis and warns of a higher risk of bleeding in combination. According to the US label, serotonin release by platelets plays an important role in haemostasis. SSRIs, fluoxetine included, may raise the risk of bleeding on their own (fluoxetine SmPC, AEMPS; fluoxetine prescribing information, US Food and Drug Administration, FDA). Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs are given with warfarin. Fluoxetine is also tightly bound to plasma proteins, and with other tightly bound drugs a shift in plasma concentrations may cause adverse effects (fluoxetine prescribing information, FDA). Fluoxetine and its active metabolite norfluoxetine are eliminated slowly, with half-lives of 4–6 and 4–16 days. Fluoxetine stays in the body for 5–6 weeks after it is stopped (fluoxetine SmPC, AEMPS).
Symptoms
The main risk is bleeding. Bruising is uncommon with fluoxetine, and other bleeding, such as gynaecological, gastrointestinal, skin or mucosal bleeding, has been reported rarely (fluoxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, bleeding with selective serotonin reuptake inhibitors ranges from ecchymoses, haematomas, nosebleeds and petechiae to life-threatening haemorrhage (fluoxetine prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).
Management
The combination is not contraindicated but needs frequent coagulation monitoring. With oral anticoagulants, check the international normalised ratio (INR) more often. It may be appropriate to adjust the anticoagulant dose both during fluoxetine treatment and after it is stopped. Take the long elimination of fluoxetine and norfluoxetine into account: the drug stays in the body for 5–6 weeks after it is stopped (fluoxetine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when fluoxetine is added and when it is stopped (acenocoumarol SmPCs, AEMPS). The Spanish fluoxetine SmPC recommends caution with oral anticoagulants. The US label says to inform patients of the increased risk of bleeding (fluoxetine SmPC, AEMPS; fluoxetine prescribing information, US Food and Drug Administration, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Prozac (fluoxetine) prescribing information (2026)– FDA label, DailyMed setid c88f33ed-6dfb-4c5e-bc01-d8e36dd97299, version 59, revised 01/2026, section 7.7 Drugs Metabolized by CYP2D6
- AEMPS: Ficha técnica: Fluoxetina, Fluoxetina Cinfa 20 mg (nº registro 63499) (2026)– AEMPS, CIMA, nº registro 63499 (Fluoxetina Cinfa 20 mg cápsulas duras EFG), revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.4 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.4 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.4
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.2